Australia's New R&D Tax Credit Expected To Inject Funds Into Local Biotech Industry - And Multinational Subsidiaries?
This article was originally published in PharmAsia News
MELBOURNE, Australia - Many in the Australian life sciences industry view the nation's new R&D Tax Credit, which became law in August 2011 with the passing of the Tax Laws Amendment (Research and Development) Bill 2010, as a marked improvement on the R&D Tax Concession it replaces
You may also be interested in...
Funding for early-stage research has been a huge problem in Australia until recently, and new funding mechanisms have come just in time as research begun a decade ago moves into development.
Australia Ranked As Second Most Expensive Country For Clinical Trials; Medicines Australia Calls For Reform
A strong currency and cumbersome rules have contributed to Australia becoming the second-most expensive country for clinical trials, and neighboring countries are taking advantage.
PERTH, Australia - Australia's biotech sector has entered a golden era, with its top 20 companies now maturing, for the first time bringing products to late-stage development, and looking to commercialize